Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The price of Pyxis Oncology Inc (NASDAQ: PYXS) closed at $1.11 in the last session, down -6.72% from day before closing price of $1.19. In other words, the price has decreased by -$6.72 from its previous closing price. On the day, 0.5 million shares were traded.
Ratios:
We take a closer look at PYXS’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 7.33 and its Current Ratio is at 7.33. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.12.
On November 08, 2024, Stephens started tracking the stock assigning a Overweight rating and target price of $13.
On August 08, 2024, Stifel started tracking the stock assigning a Buy rating and target price of $10.Stifel initiated its Buy rating on August 08, 2024, with a $10 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 26 ’24 when Connealy Pamela Ann bought 88,850 shares for $1.96 per share. The transaction valued at 174,364 led to the insider holds 1,199,143 shares of the business.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 4.09 while its Price-to-Book (P/B) ratio in mrq is 0.43.
Stock Price History:
Over the past 52 weeks, PYXS has reached a high of $6.79, while it has fallen to a 52-week low of $1.11. The 50-Day Moving Average of the stock is -24.83%, while the 200-Day Moving Average is calculated to be -62.08%.
Shares Statistics:
A total of 59.45M shares are outstanding, with a floating share count of 42.26M. Insiders hold about 28.94% of the company’s shares, while institutions hold 40.70% stake in the company.
